Terminated × Carcinoma, Non-Small-Cell Lung × Clear all Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Phase 1/2 Terminated
8 enrolled 13 charts
ALAFOSS-01
Phase 1 Terminated
17 enrolled
CONCORDE
Phase NA Terminated
21 enrolled
Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Terminated
1 enrolled
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Phase 1/2 Terminated
28 enrolled
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Phase 2 Terminated
50 enrolled 18 charts
AcceleRET-Lung
Phase 3 Terminated
223 enrolled 18 charts
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Phase 1 Terminated
29 enrolled
OPTIMUNELUNG
Phase 2 Terminated
8 enrolled
PRO1107 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
33 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
Phase 2 Terminated
93 enrolled
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Phase 2 Terminated
14 enrolled 16 charts
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
21 enrolled
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Phase 1 Terminated
64 enrolled
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Phase 1 Terminated
30 enrolled
Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer
Phase 1/2 Terminated
25 enrolled 11 charts
Tamarack
Phase 2 Terminated
192 enrolled 20 charts
Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen
Phase 1 Terminated
4 enrolled
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
Phase 1 Terminated
16 enrolled 9 charts
Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease
Phase 1 Terminated
5 enrolled
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Phase 1 Terminated
42 enrolled
PRIMING
Phase 1 Terminated
2 enrolled 10 charts
EPITOP-01
Phase 4 Terminated
40 enrolled
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
Phase 2 Terminated
3 enrolled 12 charts
Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI
Phase 1 Terminated
9 enrolled
This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091
Phase 1 Terminated
8 enrolled 10 charts
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1/2 Terminated
34 enrolled 44 charts
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Phase 1 Terminated
250 enrolled
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Phase 2 Terminated
5 enrolled 13 charts
ATLAS
Phase 2 Terminated
5 enrolled
HBI-8000
Phase 2 Terminated
5 enrolled 8 charts
BRIDGE
Phase 2 Terminated
10 enrolled
Tarlox and Sotorasib in Patients With KRAS G12C Mutations
Phase 1/2 Terminated
5 enrolled 9 charts
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
Phase 1 Terminated
227 enrolled
KEYNOTE-867
Phase 3 Terminated
448 enrolled 24 charts
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Phase 1/2 Terminated
95 enrolled
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
Phase 3 Terminated
162 enrolled
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 1/2 Terminated
31 enrolled
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
Phase 2 Terminated
12 enrolled
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Phase 2 Terminated
166 enrolled 43 charts
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase 1/2 Terminated
8 enrolled 12 charts
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer
Phase 1 Terminated
41 enrolled
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Phase 1 Terminated
30 enrolled
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
Phase 1/2 Terminated
26 enrolled 13 charts
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Phase 1 Terminated
27 enrolled
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Terminated
9 enrolled 13 charts